Cholesterol Drug

esperion

Esperion Starts Next Phase Of Cholesterol Drug Trial

The Plymouth pharma startup Esperion Therapeutics Inc. (Nasdaq: ESPR), Wednesday announced the first patient in a Phase 2b clinical study had received the first dose of ETC-1002, its lead anti-cholesterol drug.

WWJ Newsradio 950–10/30/2013

Esperion logo

Esperion Therapeutics Reports Financial Details, Corporate Update

Esperion Therapeutics Inc. (Nasdaq: ESPR), an early-stage pharmaceutical company developing a new class of cholesterol-fighting drugs, Monday provided financial figures and a corporate update.

WWJ Newsradio 950–08/12/2013

Esperion Gets $33M To Continue Work On Cholesterol Buster

The Ann Arbor biotech firm Esperion Therapeutics Inc. announced that it has completed a $33 million preferred stock financing led by new investor Longitude Capital.

WWJ Newsradio 950–04/25/2013

cerenis

Cerenis Appoints Non-Executive Director, CMO

Cerenis Therapeutics, the pharma company developing new high-density lipoprortein therapies for cardiovascular and metabolic diseases, Tuesday appointed Richard C. Pasternak to the board of directors and John F. Paolini, M.D., as Chief Medical Officer.

WWJ Newsradio 950–11/22/2011

esperion

Esperion Starts Phase 2 Trial Of Cholesterol Buster

The Plymouth pharmaceutical developer Esperion Therapeutics Thursday announced that it has initiated a Phase 2 clinical study for ETC-1002, the company’s lead product candidate.  ETC-1002 is a novel small molecule compound that has demonstrated preclinical […]

01/06/2011

Follow

Get every new post delivered to your Inbox.

Join 2,354 other followers